Compare Las Vegas Sands Corp. (LVS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Sanofi SA — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.1× Las Vegas Sands Corp.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Sanofi SA for 94 Days on average.
| LVS | SNY | |
|---|---|---|
Market Cap | $23.38B | $95.18B |
Volume | 6,994,661 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $52.34 |
52-Week Low | $35.81 | $39.51 |
Typical Hold Time | 72 Days | 94 Days |
Enterprise Value | $35.27B | $114.48B |
Dividend Yield | 3.32% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with $13.02B revenue, 12.59% net margin, and positive cash flow of $191M in 2025. Recent news highlights Sands China's community initiatives and operational milestones, while analyst consensus remains strongly bullish with a $59.78 price target.
LVS presents a compelling value opportunity with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). However, high debt levels and recent Q2 2026 earnings miss pose risks. The significant upside to analyst targets suggests potential for substantial returns if operational execution improves.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
